Skip to main content
SpringerLink
Log in

Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC–MS/MS method

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

To establish a rapid and sensitive ultra performance liquid chromatography tandem mass spectrometry (UPLC–MS/MS) method for the determination of rivaroxaban, apixaban and edoxaban in rat plasma. The analytes and the internal standard (diazepam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1 mm × 50 mm, 1.7 μm) using gradient elution with a mobile phase of acetonitrile and 0.1 % formic acid in water at a flow rate of 0.4 mL/min. The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface. The method was validated over a concentration range of 1.0–200 ng/mL for rivaroxaban, 1.0–100 ng/mL for apixaban and 1.0–500 ng/mL for edoxaban. Total time for each chromatograph was 3.5 min. The intra- and inter-day precision and accuracy of the quality control samples at low, medium, and high concentration levels exhibited relative standard deviations <10.5 % and the accuracy values ranged from −9.9 to 11.3 %. The method was successfully applied to a pharmacokinetic study of rivaroxaban, apixaban and edoxaban in rats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F (2011) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov 10:61–75

    Article  CAS  PubMed  Google Scholar 

  2. Watson J, Whiteside G, Perry C (2011) Apixaban: first global approval. Drugs 71:2079–2089

    Article  CAS  PubMed  Google Scholar 

  3. Bounameaux H, Camm AJ (2014) Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 74:1209–1231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bassand JP (2012) Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace 14:312–324

    Article  PubMed  PubMed Central  Google Scholar 

  5. Mendell J, Tachibana M, Shi M, Kunitada S (2011) Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 51:687–694

    Article  CAS  PubMed  Google Scholar 

  6. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R et al (2013) Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 75:476–487

    Article  CAS  PubMed  Google Scholar 

  7. Stampfuss J, Kubitza D, Becka M, Mueck W (2013) The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 51:549–561

    Article  CAS  PubMed  Google Scholar 

  8. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G et al (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e44S–e88S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747

    Article  PubMed  Google Scholar 

  10. Samama MM, Guinet C (2011) Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49:761–772

    Article  CAS  PubMed  Google Scholar 

  11. Barrett YC, Wang Z, Knabb RM (2013) A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb/Hemost 19:522–528

    Article  CAS  Google Scholar 

  12. Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM et al (2014) Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography: tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 12:1636–1646

    Article  CAS  PubMed  Google Scholar 

  13. Korostelev M, Bihan K, Ferreol L, Tissot N, Hulot JS, Funck-Brentano C et al (2014) Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 100:230–235

    Article  CAS  PubMed  Google Scholar 

  14. Iqbal M, Khalil NY, Imam F, Khalid Anwer M (2015) A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample. J Thromb Thrombolysis 39:79–88

    Article  CAS  PubMed  Google Scholar 

  15. Rohde G (2008) Determination of rivaroxaban–a novel, oral, direct Factor Xa inhibitor–in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B 872:43–50

    Article  CAS  Google Scholar 

  16. Pursley J, Shen JX, Schuster A, Dang OT, Lehman J, Buonarati MH et al (2014) LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column. Bioanalysis 6:2071–2082

    Article  PubMed  Google Scholar 

  17. Delavenne X, Mismetti P, Basset T (2013) Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal 78–79:150–153

    Article  PubMed  Google Scholar 

  18. Zheng N, Yuan L, Ji QC, Mangus H, Song Y, Frost C et al (2015) “Center punch” and “whole spot” bioanalysis of apixaban in human dried blood spot samples by UHPLC-MS/MS. J Chromatogr B 988:66–74

    Article  CAS  Google Scholar 

  19. Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ (2014) Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit 36:597–605

    Article  CAS  PubMed  Google Scholar 

  20. Qiu X, Wang Z, Wang B, Zhan H, Pan X, Xu RA (2014) Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by ultra high performance liquid chromatography tandem mass spectrometry and its application to a bioequivalence study. J Chromatogr B 957:110–115

    Article  CAS  Google Scholar 

  21. Qiu X, Zhao JL, Hao C, Yuan C, Tian N, Xu ZS et al (2016) Simultaneous determination of mangiferin and neomangiferin in rat plasma by UPLC-MS/MS and its application for pharmacokinetic study. J Pharm Biomed Anal 124:138–142

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People’s Republic of China

    Wan-li Zhang & Huan-jie Huang

  2. The Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, 325027, People’s Republic of China

    Dan Lou

  3. Medical College of Henan University of Science and Technology, Luoyang, 471003, People’s Republic of China

    Dong-tao Zhang & Yin Zhang

Authors
  1. Wan-li Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dan Lou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong-tao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Huan-jie Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Huan-jie Huang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Wl., Lou, D., Zhang, Dt. et al. Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC–MS/MS method. J Thromb Thrombolysis 42, 205–211 (2016). https://doi.org/10.1007/s11239-016-1367-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-016-1367-y

Keywords

Search

Navigation